JPWO2020139525A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020139525A5 JPWO2020139525A5 JP2021537848A JP2021537848A JPWO2020139525A5 JP WO2020139525 A5 JPWO2020139525 A5 JP WO2020139525A5 JP 2021537848 A JP2021537848 A JP 2021537848A JP 2021537848 A JP2021537848 A JP 2021537848A JP WO2020139525 A5 JPWO2020139525 A5 JP WO2020139525A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- betamethasone
- weight
- composition according
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 229960000951 Mycophenolic Acid Drugs 0.000 claims description 7
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims description 7
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 5
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 229950006991 betamethasone phosphate Drugs 0.000 claims description 4
- 229960005354 betamethasone sodium phosphate Drugs 0.000 claims description 4
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 3
- 229940083353 mycophenolate sodium Drugs 0.000 claims description 2
- 206010013774 Dry eye Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- UREBDLICKHMUKA-DVTGEIKXSA-N Betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- 206010067103 Ocular surface disease Diseases 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N Betamethasone 17-valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N Betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims 1
- 229960004311 Betamethasone valerate Drugs 0.000 claims 1
- 208000010217 Blepharitis Diseases 0.000 claims 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims 1
- 210000004175 Meibomian Glands Anatomy 0.000 claims 1
- 229960004648 betamethasone acetate Drugs 0.000 claims 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 claims 1
- 229960001102 betamethasone dipropionate Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 230000002981 neuropathic Effects 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007975 buffered saline Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229920001992 poloxamer 407 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 description 1
- 229940068968 Polysorbate 80 Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L disodium;2-[2-[carboxylatomethyl(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 230000001861 immunosuppresant Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862785312P | 2018-12-27 | 2018-12-27 | |
| US62/785,312 | 2018-12-27 | ||
| PCT/US2019/064371 WO2020139525A1 (en) | 2018-12-27 | 2019-12-04 | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022516099A JP2022516099A (ja) | 2022-02-24 |
| JPWO2020139525A5 true JPWO2020139525A5 (pt) | 2022-12-12 |
Family
ID=71127864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021537848A Pending JP2022516099A (ja) | 2018-12-27 | 2019-12-04 | 眼科用医薬組成物及び癌表面疾患の処置方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220071945A1 (pt) |
| EP (1) | EP3902525A4 (pt) |
| JP (1) | JP2022516099A (pt) |
| KR (1) | KR20210141448A (pt) |
| CN (1) | CN113473970A (pt) |
| AU (1) | AU2019417161B2 (pt) |
| BR (1) | BR112021012492A2 (pt) |
| CA (1) | CA3124945A1 (pt) |
| IL (1) | IL284344A (pt) |
| MX (1) | MX2021007709A (pt) |
| SG (1) | SG11202106967QA (pt) |
| WO (1) | WO2020139525A1 (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022076398A1 (en) * | 2020-10-07 | 2022-04-14 | Surface Ophthalmics, Inc. | Pharmaceutical kits and their use for treating dry eye disease |
| EP3691654A4 (en) * | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
| WO2023141334A2 (en) * | 2022-01-24 | 2023-07-27 | Surface Ophthalmics, Inc. | Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1142566E (pt) * | 2000-04-07 | 2004-02-27 | Medidom Lab | Formulacao oftalmica topica na forma de uma solucao aquosa e uso de uma ciclosporina em associacao com acido hialuronico ou um de seus sais e com polisorbato 80 |
| US7087237B2 (en) * | 2003-09-19 | 2006-08-08 | Advanced Ocular Systems Limited | Ocular solutions |
| WO2006073786A2 (en) * | 2004-12-30 | 2006-07-13 | Bausch & Lomb Incorporated | Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy |
| WO2007038687A2 (en) * | 2005-09-27 | 2007-04-05 | Aciont, Inc. | Ocular administration of immunosuppressive agents |
| JP2011527339A (ja) * | 2008-07-09 | 2011-10-27 | アスプレバ インターナショナル リミテッド | 眼障害を処置するためのミコフェノール酸ナトリウムのｐＨ特異的な溶液 |
| JP6231995B2 (ja) * | 2012-02-10 | 2017-11-15 | タイワン リポソーム カンパニー リミテッド | 眼の疾患の合併症を低減するための薬学的組成物 |
| MX2020005126A (es) * | 2012-11-08 | 2022-01-27 | Clearside Biomedical Inc | Metodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| US9789080B2 (en) * | 2015-09-04 | 2017-10-17 | Insite Vision Incorporated | Ophthalmic formulations of mycophenolic acid |
| BR112019011406A2 (pt) * | 2016-12-11 | 2019-10-15 | Seanergy Dermatology Ltd | composição método para tratar inflamação |
| CN110996904A (zh) * | 2017-05-19 | 2020-04-10 | 奥古根有限公司 | 眼用组合物及使用方法 |
| EP3691654A4 (en) * | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
-
2019
- 2019-12-04 BR BR112021012492-6A patent/BR112021012492A2/pt not_active Application Discontinuation
- 2019-12-04 CN CN201980092852.9A patent/CN113473970A/zh active Pending
- 2019-12-04 EP EP19902055.3A patent/EP3902525A4/en active Pending
- 2019-12-04 WO PCT/US2019/064371 patent/WO2020139525A1/en unknown
- 2019-12-04 US US17/418,813 patent/US20220071945A1/en active Pending
- 2019-12-04 MX MX2021007709A patent/MX2021007709A/es unknown
- 2019-12-04 SG SG11202106967QA patent/SG11202106967QA/en unknown
- 2019-12-04 JP JP2021537848A patent/JP2022516099A/ja active Pending
- 2019-12-04 AU AU2019417161A patent/AU2019417161B2/en active Active
- 2019-12-04 KR KR1020217023758A patent/KR20210141448A/ko unknown
- 2019-12-04 CA CA3124945A patent/CA3124945A1/en active Pending
-
2021
- 2021-06-24 IL IL284344A patent/IL284344A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6886502B2 (ja) | アトロピン含有水性組成物 | |
| US4829088A (en) | Medicament for the treatment of inflammations of the eye | |
| JP5524438B2 (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
| CN107865821B (zh) | 一种预防或治疗脉络膜新生血管形成的制剂 | |
| AU738413B2 (en) | Human growth hormone-containing aqueous pharmaceutical composition | |
| JP2002363097A (ja) | 安定化された凍結乾燥型医薬組成物 | |
| JP2011093923A (ja) | 点眼剤 | |
| JP4434486B2 (ja) | 医薬組成物 | |
| JP2012167132A (ja) | Ｎ−［ｏ−（ｐ−ピバロイルオキシベンゼンスルホニルアミノ）ベンゾイル］グリシン・モノナトリウム塩・４水和物の凍結乾燥製剤 | |
| JPH08291065A (ja) | 有機アミンを配合したプラノプロフェン点眼液 | |
| JP2023058566A (ja) | 安定なペプチド組成物 | |
| WO2019180199A1 (en) | Stable aqueous composition of phosphocreatine | |
| JP4757970B2 (ja) | 点眼剤組成物 | |
| JPWO2020139525A5 (pt) | ||
| EP4027977A1 (en) | Pharmaceutical composition of bimatoprost and timolol | |
| WO2012013116A1 (zh) | 含氨基酸稳定剂的替莫唑胺药物组合物及其制备方法 | |
| JPH0222223A (ja) | 医薬組成物 | |
| JP6051315B2 (ja) | 乾癬を処置するためのピドチモドの使用 | |
| KR20210032435A (ko) | 산화질소 방출 프로스타미드를 함유하는 안과용 조성물 | |
| US4328213A (en) | Stable injectable labetalol formulation | |
| JPH10338638A (ja) | 損傷皮膚修復用製剤 | |
| WO1993023032A1 (en) | Remedy for cataract and production thereof | |
| JPH059121A (ja) | 腸粘膜萎縮抑制剤 | |
| PT93897A (pt) | Processo para a preparacao de uma composicao farmaceutica de cromoglicato de sodio e carboxi-polimetileno | |
| US5093348A (en) | Pharmaceutical composition for topical ophthalmic use having improved local tolerability |